{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:39:12Z","timestamp":1793839152886,"version":"4.6.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"European Crohn\u2019s and Colitis Organisation"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Anti-tumour necrosis factor [anti-TNF] therapy is indicated for treatment of moderate to severe inflammatory bowel disease [IBD], but has a primary non-response rate of around 30%. We aim to use metabonomic and metataxonomic profiling to identify predictive biomarkers of anti-TNF response in Crohn\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with luminal Crohn\u2019s disease, commencing anti-TNF therapy, were recruited with urine, faeces, and serum samples being collected at baseline and 3-monthly. Primary response was defined according to a combination of clinical and objective markers of inflammation. Samples were measured using three UPLC-MS assays: lipid, bile acid, and Hydrophillic Interaction Liquid Chromatography [HILIC] profiling with 16S rRNA gene sequencing of faeces.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Samples were collected from 76 Crohn\u2019s disease patients who were anti-TNF na\u00efve and from 13 healthy controls. There were 11 responders, 37 non-responders, and 28 partial responders in anti-TNF-treated Crohn\u2019s patients. Histidine and cysteine were identified as biomarkers of response from polar metabolite profiling [HILIC] of serum and urine. Lipid profiling of serum and faeces found phosphocholines, ceramides, sphingomyelins, and triglycerides, and bile acid profiling identified primary bile acids to be associated with non-response to anti-TNF therapy, with higher levels of phase 2 conjugates in non-responders. Receiver operating curves for treatment response demonstrated 0.94 +\/ -0.10 [faecal lipid], 0.81 +\/- 0.17 [faecal bile acid], and 0.74 +\/- 0.15 [serum bile acid] predictive ability for anti-TNF response in Crohn\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This prospective, longitudinal cohort study of metabonomic and 16S rRNA gene sequencing analysis demonstrates that a range of metabolic biomarkers involving lipid, bile acid, and amino acid pathways may contribute to prediction of response to anti-TNF therapy in Crohn\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article has an associated podcast which can be accessed at https:\/\/academic.oup.com\/ecco-jcc\/pages\/podcast<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaa039","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T15:16:00Z","timestamp":1582816560000},"page":"1090-1102","source":"Crossref","is-referenced-by-count":109,"title":["Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn\u2019s Disease"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-1948","authenticated-orcid":false,"given":"N S","family":"Ding","sequence":"first","affiliation":[{"name":"St Vincent's Hospital, Inflammatory Bowel Disease, Melbourne, VIC, Australia"},{"name":"St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK"},{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A K","family":"McDonald","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Surgery and Cancer, St Mary\u2019s Hospital, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Perdones-Montero","sequence":"additional","affiliation":[{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas N","family":"Rees","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Surgery and Cancer, St Mary\u2019s Hospital, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S O","family":"Adegbola","sequence":"additional","affiliation":[{"name":"St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK"},{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Misra","sequence":"additional","affiliation":[{"name":"St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK"},{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hendy","sequence":"additional","affiliation":[{"name":"St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Penez","sequence":"additional","affiliation":[{"name":"St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Marchesi","sequence":"additional","affiliation":[{"name":"School of Biosciences, Cardiff University, Cardiff, UK"},{"name":"Division of Digestive Diseases, Department of Surgery and Cancer, St Mary\u2019s Hospital, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Holmes","sequence":"additional","affiliation":[{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"},{"name":"Institute of Health Futures, Murdoch University, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Sarafian","sequence":"additional","affiliation":[{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Hart","sequence":"additional","affiliation":[{"name":"St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK"},{"name":"Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"2020090711040557900_CIT0001","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"2020090711040557900_CIT0002","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020090711040557900_CIT0003","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/gutjnl-2012-303954","article-title":"Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome","volume":"62","author":"Knights","year":"2013","journal-title":"Gut"},{"key":"2020090711040557900_CIT0004","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/003655200451207","article-title":"Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study","volume":"35","author":"Orholm","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"2020090711040557900_CIT0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/gut.29.7.990","article-title":"Ulcerative colitis and Crohn\u2019s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking","volume":"29","author":"Tysk","year":"1988","journal-title":"Gut"},{"key":"2020090711040557900_CIT0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"2020090711040557900_CIT0007","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"key":"2020090711040557900_CIT0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"2020090711040557900_CIT0009","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020090711040557900_CIT0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"2020090711040557900_CIT0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2020090711040557900_CIT0012","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/ajg.2016.441","article-title":"Biomarkers in search of precision medicine in IBD","volume":"111","author":"Boyapati","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2020090711040557900_CIT0013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"2020090711040557900_CIT0014","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/apt.15126","article-title":"Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn\u2019s disease","volume":"49","author":"Verstockt","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2020090711040557900_CIT0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"2020090711040557900_CIT0016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin \u03b1E and granzyme A in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0017","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"key":"2020090711040557900_CIT0018","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2010.10.036","article-title":"Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis","volume":"139","author":"Sartor","year":"2010","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0019","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: current status and the future ahead","volume":"146","author":"Kostic","year":"2014","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ibd.21339","article-title":"Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases","volume":"17","author":"Frank","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2020090711040557900_CIT0021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.chom.2008.05.001","article-title":"Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases","volume":"3","author":"Peterson","year":"2008","journal-title":"Cell Host Microbe"},{"key":"2020090711040557900_CIT0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/gast.2002.30294","article-title":"Mucosal flora in inflammatory bowel disease","volume":"122","author":"Swidsinski","year":"2002","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0023","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/gutjnl-2017-315352","article-title":"Guiding longitudinal sampling in IBD cohorts","volume":"67","author":"Vazquez-Baeza","year":"2018","journal-title":"Gut"},{"key":"2020090711040557900_CIT0024","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/gutjnl-2013-306423","article-title":"Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD","volume":"64","author":"De Preter","year":"2015","journal-title":"Gut"},{"key":"2020090711040557900_CIT0025","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","article-title":"Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment","volume":"13","author":"Morgan","year":"2012","journal-title":"Genome Biol"},{"key":"2020090711040557900_CIT0026","doi-asserted-by":"crossref","first-page":"e6386","DOI":"10.1371\/journal.pone.0006386","article-title":"Metabolomics reveals metabolic biomarkers of Crohn\u2019s disease","volume":"4","author":"Jansson","year":"2009","journal-title":"PLoS One"},{"key":"2020090711040557900_CIT0027","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/pr060470d","article-title":"Rapid and noninvasive metabonomic characterization of inflammatory bowel disease","volume":"6","author":"Marchesi","year":"2007","journal-title":"J Proteome Res"},{"key":"2020090711040557900_CIT0028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1126\/science.aad3503","article-title":"Population-level analysis of gut microbiome variation","volume":"352","author":"Falony","year":"2016","journal-title":"Science"},{"key":"2020090711040557900_CIT0029","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(80)91577-9","article-title":"Measuring Crohn\u2019s disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2020090711040557900_CIT0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0031","first-page":"1","volume-title":"16S Metagenomic Sequencing Library Preparation","author":"Illumina","year":"2013"},{"key":"2020090711040557900_CIT0032","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1128\/AEM.01043-13","article-title":"Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform","volume":"79","author":"Kozich","year":"2013","journal-title":"Appl Environ Microbiol"},{"key":"2020090711040557900_CIT0033","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1128\/AEM.00062-07","article-title":"Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy","volume":"73","author":"Wang","year":"2007","journal-title":"Appl Environ Microbiol"},{"key":"2020090711040557900_CIT0034","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/bioinformatics\/btu494","article-title":"STAMP: statistical analysis of taxonomic and functional profiles","volume":"30","author":"Parks","year":"2014","journal-title":"Bioinformatics"},{"key":"2020090711040557900_CIT0035","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.analchem.5b01556","article-title":"Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry","volume":"87","author":"Sarafian","year":"2015","journal-title":"Anal Chem"},{"key":"2020090711040557900_CIT0036","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/(SICI)1099-128X(199609)10:5\/6<521::AID-CEM448>3.0.CO;2-J","article-title":"Model validation by permutation tests: applications to variable selection","volume":"10","author":"Lindgren","year":"1996","journal-title":"J Chemometrics"},{"key":"2020090711040557900_CIT0037","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2020090711040557900_CIT0038","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nrgastro.2015.114","article-title":"The promise of metabolic phenotyping in gastroenterology and hepatology","volume":"12","author":"Holmes","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020090711040557900_CIT0039","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2019.07.025","article-title":"Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases","volume":"157","author":"Aden","year":"2019","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-017-1311-y","article-title":"Alterations in lipid, amino acid, and energy metabolism distinguish Crohn\u2019s disease from ulcerative colitis and control subjects by serum metabolomic profiling","volume":"14","author":"Scoville","year":"2018","journal-title":"Metabolomics"},{"key":"2020090711040557900_CIT0041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"key":"2020090711040557900_CIT0042","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","article-title":"Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases","volume":"62","author":"Duboc","year":"2013","journal-title":"Gut"},{"key":"2020090711040557900_CIT0043","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12917-016-0736-2","article-title":"Does canine inflammatory bowel disease influence gut microbial profile and host metabolism?","volume":"12","author":"Xu","year":"2016","journal-title":"BMC Vet Res"},{"key":"2020090711040557900_CIT0044","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn\u2019s disease patients predicts non-response to infliximab treatment","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2020090711040557900_CIT0045","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.3748\/wjg.14.5584","article-title":"Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease","volume":"14","author":"Wagner","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2020090711040557900_CIT0046","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajgsup.2016.17","article-title":"Using markers in IBD to predict disease and treatment outcomes: rationale and a review of current status","volume":"3","author":"Lichtenstein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2020090711040557900_CIT0047","doi-asserted-by":"crossref","first-page":"G906","DOI":"10.1152\/ajpgi.00043.2007","article-title":"Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation","volume":"294","author":"Raimondi","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2020090711040557900_CIT0048","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fphar.2016.00094","article-title":"Activation-induced cell death of dendritic cells is dependent on sphingosine kinase 1","volume":"7","author":"Schwiebs","year":"2016","journal-title":"Front Pharmacol"},{"key":"2020090711040557900_CIT0049","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2020090711040557900_CIT0050","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/apt.13333","article-title":"Systematic review: bile acids and intestinal inflammation - luminal aggressors or regulators of mucosal defence?","volume":"42","author":"Pavlidis","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2020090711040557900_CIT0051","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fmicb.2013.00396","article-title":"Bile resistance mechanisms in Lactobacillus and Bifidobacterium","volume":"4","author":"Ruiz","year":"2013","journal-title":"Front Microbiol"},{"key":"2020090711040557900_CIT0052","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/mi.2017.58","article-title":"Diacylglycerol kinase synthesized by commensal Lactobacillus reuteri diminishes protein kinase C phosphorylation and histamine-mediated signaling in the mammalian intestinal epithelium","volume":"11","author":"Ganesh","year":"2018","journal-title":"Mucosal Immunol"},{"key":"2020090711040557900_CIT0053","doi-asserted-by":"crossref","first-page":"e0140716","DOI":"10.1371\/journal.pone.0140716","article-title":"Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission","volume":"10","author":"Hisamatsu","year":"2015","journal-title":"PLoS One"},{"key":"2020090711040557900_CIT0054","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1053\/j.gastro.2008.09.062","article-title":"Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages","volume":"136","author":"Andou","year":"2009","journal-title":"Gastroenterology"},{"key":"2020090711040557900_CIT0055","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1021\/pr2007973","article-title":"Metabolic phenotyping of the Crohn\u2019s disease-like IBD etiopathology in the TNF[\u0394ARE\/WT] mouse model","volume":"10","author":"Baur","year":"2011","journal-title":"J Proteome Res"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa039\/33048981\/jjaa039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/8\/1090\/33722612\/jjaa039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/8\/1090\/33722612\/jjaa039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T11:04:57Z","timestamp":1599476697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/8\/1090\/5771407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,2]]},"published-print":{"date-parts":[[2020,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa039","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,1]]},"published":{"date-parts":[[2020,3,2]]}}}